LYL845 is an autologous TIL therapy produced with epigenetic reprogramming, which generates populations of tumor-reactive T cells with stem-like qualities and a more favorable phenotype (including CD8 skewing) [44]. The gene discussed is CD8A; the disease is neoplasm.